Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL

Ki vehet részt

• Histologically confirmed Non-GCB DLBCL (per 2016 WHO diagnostic criteria)
• Whole-body PET/CT performed within 28 days prior to study enrollment demonstrating at least one measurable lesion (per 2014 Lugano criteria)
• Age 18-65 years, with expected survival >3 months
• No prior anti-lymphoma treatment
• Signed written informed consent and ability to comply with protocol-required visits and procedures
• ECOG performance status 0-2
• Adequate organ and bone marrow function, defined as follows:; Hematology: Absolute neutrophil count (ANC) ≥1×10⁹/L, platelet count (PLT) ≥50×10⁹/L, hemoglobin (HGB) ≥8.0 g/dL; no granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 7 days prior to testing; Hepatic function: Total bilirubin (TBIL) ≤1.5×upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN; Renal function: Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCR) ≥50 mL/min; Cardiac function: NYHA Class III or below; left ventricular ejection fraction ≥50% by echocardiography; Coagulation: International normalized ratio (INR) ≤1.5×ULN, activated partial thromboplastin time (APTT) ≤ULN +10s, and prothrombin time (PT) ≤ULN +3s
• Women of childbearing potential or male subjects with partners of childbearing potential must use effective contraception throughout the treatment period and for 90 days after the last dose

Ki nem vehet részt

• Concurrent malignancy requiring treatment or intervention
• Major surgery within 4 weeks prior to treatment (excluding vascular access catheter placement or biopsy)
• Receipt of other investigational agents within 1 month prior to first dose
• History of hypersensitivity to the study drug, drugs of the same class, or excipients
• Presence of any life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's opinion, may affect patient safety or compliance with study procedures
• Uncontrolled cardiac symptoms or disease, including: i. NYHA Class II or higher heart failure; ii. Unstable angina; iii. Myocardial infarction within 1 year; iv. Clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention
• Active bleeding
• Active, uncontrolled systemic bacterial, viral, fungal, or parasitic infection (excluding onychomycosis), or other clinically significant active disease process that, in the investigator's opinion, renders the patient unsuitable for clinical trial participation
• Known history of human immunodeficiency virus (HIV) infection and/or acquired immunodeficiency syndrome
• Exclusion of patients with active chronic hepatitis B or active hepatitis C. Patients with positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C virus antibody at screening must undergo further HBV-DNA and HCV-RNA testing. Patients with stable hepatitis B (HBV-DNA <2500 copies/mL or 500 IU/mL) on antiviral therapy and cured hepatitis C patients (below the limit of detection) may be enrolled
• Definitive history of neurological or psychiatric disorder, including epilepsy or dementia
• Central nervous system involvement
• Pregnant or lactating women
• Any other factors that, in the investigator's opinion, may affect the evaluation of efficacy or safety in this study